However, low HER2 expression in lymph node-negative patients was also an independent poor prognostic factor for DFS, but further large-scale prospective studies should be conducted to confirm whether low HER2 expression could be used as a reference indicator for further intensive treatment in early-stage breast cancer. Here, ERBB2 is linked to breast carcinoma.